Drug Trial Radar · NCT01613118
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Mar 2014
Primary completion
Jun 2016
Study completion Mar 25, 2024
Sponsor
- Lead sponsor
- Travere Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
Conditions
- Focal Segmental Glomerulosclerosis
Interventions
RE-021 (Sparsentan)Drug
Oral, once-daily
IrbesartanDrug
Oral, once-daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Urine Protein/Creatinine (Up/C)Time frame: 8 weeks
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
Balboa Nephrology Medical Group
San Diego, California
Los Angeles Biomedical Research Institute
Torrance, California
Colorado Kidney Care
Denver, Colorado
University of Miami Miller School of Medicine
Miami, Florida
Miami Children's Hospital
Miami, Florida
University of Iowa Children's Hospital
Iowa City, Iowa
Renal and Transplant Associates of New England, PC
Springfield, Massachusetts
University of Minnesota
Minneapolis, Minnesota
The Children's Mercy Hospital
Kansas City, Missouri
NYU Langone Medical Center
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center
New York, New York
SUNY Stony Brook Hospital
Stony Brook, New York
UNC Kidney Center, Pediatrics
Chapel Hill, North Carolina
University North Carolina (UNC) Kidney Center
Chapel Hill, North Carolina
Akron Nephrology Associates
Akron, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio
Unversity of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Northeast Clinical Research Center
Bethlehem, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Temple University School of Medicine
Philadelphia, Pennsylvania
University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Clinical Advancement Center
San Antonio, Texas
Southern Utah Kidney and Hypertension Center
St. George, Utah
University of Washington
Seattle, Washington
Catholic Health Initiatives Franciscan
Tacoma, Washington
Marshfield Clinic Research Foundation
Marshfield, Wisconsin
General Teaching Hospital Prague
Prague, Czechia
Azienda Ospedaliero Universitaria Policlinico di Bari
Bari, Italy
Azienda Ospedaliero Universitaria Careggi
Florence, Italy
IRCCS Istituti Clinici Maugeri
Pavia, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.